Under a dual-mode narrative, Na'an Biotech launches a coordinated offensive.-TONACEA

Under a dual-mode narrative, Na'an Biotech launches a coordinated offensive.

Update time:

2026-04-24 08:19

Reads:

Every April, the global cancer research community turns its attention to the Annual Meeting of the American Association for Cancer Research (AACR). Held in San Diego, USA from April 17 to 22, 2026, the AACR gathering unfolded as scheduled.

A total of 104 Chinese pharmaceutical enterprises presented more than 250 innovative drugs, and over 30 China-led studies were selected for the meeting’s flagship oral presentation sessions. ADC therapies remained firmly in the spotlight, with well-established targets including HER2, TROP2, EGFR and Claudin 18.2 repeatedly featured across conference posters.

Amid this bustling landscape, Na’an Biotech, a Shanxi-based biotech firm, has emerged with a distinctive strategic approach.

Two of the company’s studies were accepted for this year’s conference. One focuses on a HER2/TF bispecific ADC/RDC, selected for the drug resistance thematic session; the other centers on a TF-targeted radiopharmaceutical RDC, featured in the integrated diagnosis and treatment track. Though both revolve around the same core target, they adopt two entirely distinct technological pathways. This deliberate arrangement reflects Na’an Biotech’s overarching strategy centered on the co-development of ADCs and RDCs.

Beneath this layout lies a more forward-looking strategic logic. Na’an Biotech’s core competitive advantage stems from its dual antibody portfolio: B836, an ADC candidate, and RB02, an RDC candidate, both built on a shared HER2+TF bispecific antibody framework. This dual-modal, parallel development model based on a unified antibody backbone remains rare among China’s emerging innovative drug developers.

This raises a critical question: Why is this biotech company advancing both ADC and RDC candidates against an identical target pair? And why place strategic bets on a bispecific antibody-driven, dual-modal technological pathway?

TONACEA 01: The “1+1＞2” Synergy Model

Over the past two decades, oncology drug development has followed a dominant paradigm: identify a single target, adopt one mechanism of action, and advance a standalone therapeutic product.

Small-molecule targeted agents, monoclonal antibodies, and the rapidly rising class of ADCs have largely adhered to this linear model. Developers progress along a simplified causal chain linking target and mechanism, minimizing variables to enhance predictability in clinical development.

This methodology has yielded countless blockbuster therapies and shaped the industry’s entrenched R&D mindset. Nevertheless, treatment regimens defined by single targets and singular mechanisms are increasingly hitting efficacy ceilings in oncology care.

Tumor heterogeneity dictates that no single therapeutic modality can fully eradicate all cancer cells. HER2-targeted ADCs may lose efficacy due to antigen downregulation; PD-1 inhibitors face resistance from T-cell exhaustion; and small-molecule targeted agents often fail to cover all driver mutation subclones.

The clear industry signal emerging from JPM 2026 points to a strategic shift: developers are prioritizing target differentiation, full-stack technological iteration, and combination therapy exploration. Partnership data underscores this transition. In 2025, outbound licensing deals for Chinese innovative drugs exceeded $130 billion in total value, hitting an all-time high. A close analysis of these transactions reveals that multinational corporations are shifting focus—from acquiring late-stage standalone assets to securing integrated target portfolios and mechanism synergy capabilities.

For instance, the over $13 billion collaboration between Qiguang Dejian, U.S.-based Biohaven and South Korea’s AimedBio includes global rights to a first-in-class FGFR3-targeted ADC, alongside a joint development platform covering 21 ADC targets. HaploTherapeutics has established a strategic partnership with BMS for multispecific antibody discovery, integrating its proprietary antibody platform into BMS’s global R&D system.

Combination strategies—IO plus ADCs, IO plus bispecific antibodies, IO plus protein degraders—are evolving from academic hypotheses into mainstream clinical practice. This inspires a pivotal inquiry: can dual-mechanism synergy be realized at an earlier R&D stage through a unified technological platform?

The inherent structural similarities between ADCs and RDCs offer a viable solution. Both modalities share a modular design: a targeting ligand, a linker, and an effector payload. ADCs deliver highly potent cytotoxic small molecules to tumor cells for precise localized killing. RDCs eliminate cancer via radiological energy, featuring a broader radius of action to target low-antigen and heterogeneous subclones, while enabling diagnostic molecular imaging.

In short, a shared antibody backbone capable of carrying both cytotoxic chemical payloads and radionuclides can form a closed-loop system integrating diagnosis and treatment, as well as chemical and radiological tumor elimination.

Na’an Biotech has pioneered this field with a fully validated technical solution.

TONACEA 02: Na’an Biotech’s Differentiated Solution

To understand Na’an Biotech’s strategic choices, it is essential to examine the TF target.

Tissue Factor (TF) is highly overexpressed in a broad spectrum of solid tumors, including cervical cancer, head and neck cancer, colorectal cancer, non-small cell lung cancer and pancreatic cancer, with limited expression in healthy tissues. It is a clinically validated target for ADC development.

Kaplan-Meier survival analyses demonstrate that elevated TF expression is strongly correlated with poor prognosis in renal and pancreatic cancers. By activating the JAK2-STAT5 signaling pathway, TF drives uncontrolled cancer cell proliferation and inhibits apoptosis, making it a high-value therapeutic target.

Crucially, TF plays multifaceted roles in tumor progression, regulating angiogenesis, microenvironmental coagulation and inflammation. This biological complexity endows TF-targeted interventions with natural potential for multi-mechanism synergy. Vistusertib, the world’s first TF-targeted ADC, gained approval in 2026 for recurrent or metastatic cervical cancer, conclusively validating the target’s druggability.

Chinese developers have kept pace with global progress. Leveraging preclinical validation of the TF target, T320, Na’an Biotech’s flagship TF monoclonal antibody ADC, has secured clinical trial approvals in China, the United States and Australia. It has achieved over 90% tumor inhibition in pancreatic cancer animal models and received FDA Orphan Drug Designation for pancreatic cancer in May 2024.

RT01, a TF monoclonal antibody-based RDC, has completed foundational research for integrated diagnosis and treatment. In February 2026, the company announced the first patient dosing in an investigator-initiated trial (IIT). Its zirconium-89 diagnostic radiopharmaceutical enables clear visualization of tumor lesions. In preclinical models, a single administration of 200μCi lutetium-177-labeled RT01 delivered robust anti-tumor efficacy with no severe adverse events observed.

Solid preclinical and early clinical data for these two monoclonal antibody candidates validate the TF antibody platform. Yet Na’an Biotech’s true differentiation extends far further.

Given the widespread co-expression of HER2 and TF in breast, gastric, lung, pancreatic and other solid tumors, the company has engineered the bispecific antibody candidates B836 and RB02, targeting both HER2 and TF simultaneously. The dual-target design broadens potential indications and enhances tumor selectivity and cellular internalization through synergistic antigen recognition.

Preclinical data confirms that the bispecific antibodies RB02 and B836 exhibit significantly higher tumor binding and internalization rates than monospecific HER2 and TF antibodies.

In preclinical studies, the bispecific ADC B836 maintains potent anti-tumor activity in low HER2-expression models, outperforming trastuzumab deruxtecan (DS8201) in overall tumor suppression. GLP toxicology studies in cynomolgus monkeys establish a highest non-severely toxic dose (HNSTD) of 5mg/kg, with no observed ocular toxicity or interstitial lung disease commonly associated with DS8201, supporting a favorable safety profile.

The identical bispecific antibody backbone has been further engineered into the RDC candidate RB02. Optimized through antibody engineering to improve in vivo distribution, SPECT/CT dynamic imaging confirms that lutetium-177-labeled RB02 accumulates continuously in tumor tissues over time, while radiation signals in healthy background tissues diminish rapidly. The optimized bispecific RDC exhibits markedly reduced non-specific accumulation in the kidneys and liver, substantially lowering off-target radiation risks.

In oncology animal models, a single 200μCi dose of ¹⁷⁷Lu-RB02 delivers potent tumor suppression, surpassing the anti-tumor efficacy of DS8201. Treated animals maintained stable body weight with no serious toxicities. Supported by compelling preclinical results, RB02 is poised to enter IIT clinical research.

Na’an Biotech’s ADC & RDC Pipeline Layout

TONACEA 03: A New Coordinate for BD Collaboration

The nuclear medicine boom defined 2023, ADC investment surged across capital markets in 2024, and 2025 witnessed a wave of outbound licensing for bispecific antibody therapies led by VEGF/PD-(L)1 combinations. Positioned at the intersection of these three industry trends, Na’an Biotech stands out prominently.

From the monotherapy validation of T320 and the clinical breakthrough of RT01, to the dual-modal bispecific pipeline of B836 and RB02, the company has built a tiered product portfolio targeting TF and the HER2+TF dual target.

This integrated pipeline is underpinned by a unified core logic: centered on the proprietary BioLattix platform, a shared antibody backbone branches into parallel ADC and RDC development pathways, enabling dual validation of target value via cytotoxic chemotherapy delivery and radiological energy delivery.

Pipeline progress represents visible outcomes, while platform capability constitutes the underlying foundation. The BioLattix platform delivers three core strengths: differentiated target combinations, multi-mechanism risk mitigation, and an open, adaptable antibody framework system.

1. Differentiated Target Combinations

Partners accessing the BioLattix platform gain priority access to differentiated assets targeting TF and the HER2+TF dual target. TF has achieved clinical validation in cervical cancer and other indications, while the market remains underserved. The HER2+TF dual-target modality occupies an untapped market with no approved competitors—and this is only the starting point. Leveraging the same platform logic, Na’an Biotech is advancing a robust pipeline of bispecific antibodies and dual-toxin candidates against multiple novel target pairs, unlocking extensive long-term indication potential.

Most importantly, a single antibody ligand can generate paired ADC and RDC candidates. This provides partners not with isolated single assets, but with a complete dual-modal therapeutic system combining precise chemotherapy and targeted internal radiotherapy.

Diagnostic radiopharmaceuticals enable visual lesion detection, therapeutic RDCs deliver localized anti-tumor radiation, and ADCs support sequential combination regimens. All three modalities share a unified antibody backbone, unlocking parallel commercial value across two distinct technological pathways. Amid a crowded global RDC landscape dominated by PSMA and SSTR targets, and over 70 saturated domestic radiopharmaceutical pipelines, this dual-target, dual-modality model builds robust moats in both target selection and molecular design.

2. Mechanism-Driven Risk Hedging

A core design principle of the BioLattix platform is dual-track validation for individual targets through independent ADC and RDC mechanisms. Chemical cytotoxicity and radiological therapy operate via distinct pathways with divergent resistance mechanisms, serving as mutual strategic backups. Should one modality encounter clinical safety or efficacy challenges, the other can advance independently, preventing total pipeline depreciation.

This embedded risk diversification framework offers inherent risk control for collaboration partners. It enables in-platform mechanistic diversification for single-target assets without additional R&D investment.

3. Rapid Candidate Derivation

The full-chain integrated architecture of the BioLattix platform delivers strong modular adaptability. In theory, validated targets or proprietary antibody sequences can be rapidly engineered into matched ADC or RDC candidates without rebuilding complex conjugation systems from scratch.

This shared antibody backbone model empowers sustainable, differentiated pipeline innovation—a collaboration model exemplified by the strategic partnership between AstraZeneca and HaploTherapeutics. Na’an Biotech’s HER2+TF bispecific program marks the initial milestone, with expanded target combinations defining its long-term growth potential.

Dual study selections at AACR 2026 serve as powerful external validation of Na’an Biotech’s technological prowess. Beyond conference highlights, the company has established a fully validated dual-modal technological system featuring complementary mechanisms, built-in risk diversification, and open collaborative interfaces, supported by comprehensive preclinical and early clinical data.

The company has garnered widespread industry attention; its next milestone lies in securing high-caliber strategic partners capable of scaling this integrated platform. A pivotal industry transition for Na’an Biotech is expected to arrive in the near future.

Where lies the next BD opportunity amid the fiercely competitive PD‑1/VEGF landscape?

Decree No. 818: Who Will Be Left Out?